Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07526961) titled 'Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland' on April 8.

Study Type: Observational

Primary Sponsor: Bristol-Myers Squibb

Condition: Non-Small Cell Lung Cancer

Intervention: Combination Product: Nivolumab + Ipilimumab + Chemotherapy

Recruitment Status: Not recruiting

Date of First Enrollment: December 1, 2025

Target Sample Size: 240

Countries of Recruitment: Poland

To know more, visit https://clinicaltrials.gov/study/NCT07526961

Disclaimer: Curated by HT Syndication....